ABclonal

ABclonal relies on its antibody and protein R&D center in Boston, USA, its antibody production base in Biolake (Wuhan), China, and its molecular enzyme R&D center in Zhangjiang, Shanghai. It has assembled a scientific team of more than ten top global PhDs in molecular and immunology fields from Harvard University, MIT, Fudan University, Shanghai Jiao Tong University, the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences, and Wuhan University, and is committed to research on antibody and protein technologies. The company's main business includes research antibodies, molecular enzyme products, NGS library preparation kits, active recombinant proteins, diagnostic antigen and antibody raw materials, ELISA kits, and CRO services. CRO services mainly include antibody and protein technical services, gene and peptide synthesis technical services, immunological detection technical services, and ChIP-seq technical services. The company focuses on serving research institutes, drug R&D organizations, and diagnostic industrial customers worldwide, providing customers with high-quality products and professional services. For many years, the company has been focused on the construction of antibody platforms and protein platforms, continuously introducing advanced antibody and protein technologies to optimize these two major platforms, and striving to reach the world's top level. The antibody platforms include the rabbit polyclonal antibody platform, the mouse monoclonal antibody platform, and the newly introduced rabbit monoclonal antibody platform. Among them, the human genome polyclonal antibody program of the rabbit polyclonal antibody platform has basically entered the final stage of R&D; the mouse monoclonal antibody platform can support more than 500 CRO service orders per year worldwide and the development of diagnostic antibody reagents; the rabbit monoclonal antibody platform is dedicated to the development of globally popular research and diagnostic antibody reagents. The protein platform is devoted to the technical development of world-leading molecular enzyme reagents and the optimization of four major protein expression technologies in prokaryotic and eukaryotic systems. The long-planned GMP production lines for molecular enzymes and active recombinant proteins are about to be completed. ABclonal's R&D platforms and market channels are both important, like the two strands of DNA, supporting each other and advancing together. The company's mission is to build a world-leading antibody and protein reagent brand. Enterprise advantages: rich scientific research resources, a professional scientist team, a complete global channel network, and high-quality molecular and immunological products. Enterprise history: In 2006, ABclonal was founded in Cambridge, Boston, USA, focusing on CRO technical services such as antibody preparation and peptide synthesis. In 2008, ABclonal officially launched the human genome antibody library R&D program and launched an antibody R&D program for 20,000 protein targets. In 2011, ABclonal established an antibody production base and laboratory animal center in China, settled in Biolake (Wuhan), and officially launched the human genome antibody library R&D program. From 2012 to 2015, ABclonal's antibody R&D scale reached 4,000 projects per year, and more than 10,000 antibody products were successfully launched successively. Its global channels covered most countries in the United States, Europe, and China, and it established two major inventory points in Boston, USA, and Wuhan, China. Its direct sales channels in China covered Beijing, Shanghai, Nanjing, and Wuhan, and its domestic authorized distributors exceeded 30. In 2016, ABclonal completed tens of millions of US dollars in financing that year. In the same year, it established an antibody and protein center in Boston, USA. The company's CRO services such as antibodies and proteins covered nearly 50 countries worldwide. In 2017, ABclonal established a molecular enzyme R&D center in Zhangjiang, Shanghai, and began to enter the fields of molecular enzyme reagents and NGS library preparation kits. In the first half of 2018-2019, it completed nearly 100 million yuan in Series B financing. Rabbit monoclonal antibody technology was implemented in Wuhan, and a European branch and office were established; a Japanese branch was established. In 2020, it completed 600 million yuan in Series C financing. After resuming work, it developed COVID-19 protein products and proteinase K products, and exceeded its annual business targets ahead of schedule. Core technologies: Antibody platform: large-scale polyclonal antibody platform, mouse monoclonal antibody platform, rabbit monoclonal antibody platform, ELISA Kit R&D platform, antibody sequencing platform. Protein platform: molecular enzyme platform, large-scale prokaryotic system protein platform, well-established eukaryotic system protein platform, GMP-grade pharmaceutical protein development platform.